Adverse events associated with psychotropic treatment in African American children and adolescents

Journal of the National Medical Association

Volumn 102, Issue 5, 2010, Pages 375-383

  Jerrell, Jeanette M ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Children adolescents; Drugs; Mental health

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXAPRAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; ISOCARBOXAZID; LITHIUM; MAPROTILINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRANQUILIZER; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; COMORBIDITY; CONTROLLED STUDY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; ETHNICITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORTHOSTATIC HYPOTENSION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK FACTOR; SEDATION; SEIZURE; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; UNITED STATES; WEIGHT GAIN;

EID: 77953143536     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30572-1     Document Type: Article

References (37)

1. Sorof JM, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40:441-447.
2. Flynn JT. What's new in pediatric hypertension? Curr Hypertens Rep. 2001;3:503-510.
3. Baker S, Barlow S, Cochran W, et al. Overweight children and adolescents: A clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenter Nutrition. 2005;40:533-543.
4. Strauss RS. Childhood obesity. Pediatr Gastroenter. 2002;49:175-201.
5. McClellan J, Sikich L, Findling RL, et.al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): Rationale, Design, and Methods. J Am Acad Child Adolesc Psychiatry. 2007;46:969-978.
6. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disorders. 2003; 5(suppl 2):62-79.
7. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
8. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167-181.
9. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850.
10. Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med. 2007;357:2329-2337.
11. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-685.
12. McIntyre RS, Jerrell JM. Polypharmacy in children and adolescents with major depressive disorder. J Clin Psychiatry. 2009;70:240-246.
13. Kaiser Family Foundation. Distribution of Non-elderly with Medicaid by Race 2007. Clients 0-18 Covered by Medicaid 2007. http://statehealth-facts.org/. Accessed August 26, 2009.
14. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second generation antipsychotic medications in children and adolescents. J Child and Adolesc Psychopharm. 2004;14:372-394.
15. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am. 2006;15:177-206.
16. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Acad Child Adolesc Psychiatry. 2007;46:687-700.
17. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771-791.
18. Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol. 2005;9:533-550.
19. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(suppl 7):29-40.
20. Sikitch L, Frazier JA, McClellan J, et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder. Am J Psychiatry. 2008;165:1420-1431.
21. Correll CU, Manu P, Olshanskiy V, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.
22. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158:753-759.
23. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17-25.
24. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with SSRI treatment for depression: Patient report versus physician estimate. J Clin Psychiatry. 2004;65:959-965.
25. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14:175-182.
26. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Curr Pharmaceut Des. 2004;10:2463-2475.
27. To SE, Zepf RA, Woods AG. The symptoms, neurobiology, and current pharmacological treatment of depression. J Neuroscience Nursing. 2005;37:102-107.
28. Francis PD. Effects of psychotropic medications on pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr. 2002;14:224-230.
29. Burke MJ, Lincoln J. Mood disorders. In: Bakel RE, Bope ET, eds. Conn's current therapy 2006. Philadelphia PA: WB Saunders Co.; 2006, 1361-1370.
30. Cohen D, Gerardin P, Mazet P, Purper-Ouakali D, Flament MF. Pharmacological treatment of adolescent major depression. J Child Adolesc Psychopharm. 2004;14:19-31.
31. Hirschfeld RMA. The role of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):3-4. (Pubitemid 40461405)
32. Gold Standard, Inc. Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline: Adverse Reactions. http://www.mdconsult.com. Accessed January 30, 2008.
33. Keck PE. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry. 2005;66(suppl 3):5-11.
34. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006;5:157-168.
35. Wonodi I, Reeves G, Carmichael D, et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord. 2007;22:1777-1782.
36. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv. 1999;50:827-829.
37. Mark TL, Buck JA, Dilonardo JD, Coffey RM, Chalk M. Medicaid expenditures on behavioral health care. Psychiatr Serv. 2003;54:188-194.